Pharsight

1. Tibsovo patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10610125	August, 2022	Terminated-Settled	Servier Pharmaceuticals LLC et al.	Rigel Pharmaceuticals, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9850277	SERVIER	Therapeutically active compositions and their methods of use	Jan, 2033 (9 years from now)
US9474779	SERVIER	Therapeutically active compositions and their methods of use	Aug, 2033 (9 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125	SERVIER	Methods and compositions for cell-proliferation-related disorders	Jun, 2030 (6 years from now)
US10717764	SERVIER	Therapeutically active compounds and their methods of use	Jan, 2033 (9 years from now)
US10799490	SERVIER	Pharmaceutical compositions of therapeutically active compounds	Mar, 2035 (11 years from now)
US10449184	SERVIER	Pharmaceutical compositions of therapeutically active compounds	Mar, 2035 (11 years from now)
US9968595	SERVIER	Pharmaceutical compositions of therapeutically active compounds	Mar, 2035 (11 years from now)
US10653710	SERVIER	Combination therapy for treating malignancies	Oct, 2036 (13 years from now)
US10980788	SERVIER	Therapy for treating malignancies	Jun, 2039 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 20, 2023
Orphan Drug Exclusivity (ODE)	Aug 25, 2028
New Indication (I)	May 25, 2025

Drugs and Companies using IVOSIDENIB ingredient

NCE-1 date: 2022-07-20

Market Authorisation Date: 20 July, 2018

Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketog...

Dosage: TABLET;ORAL